ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP32-17 Pharmacy Benefit Update - Dispense as Written (DAW) 1 Clarification
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2017
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 3071 - 3080 လၢ 3273 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P55-17 Prior Authorization Requirement for Orthognathic Surgery
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 11, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P54-17 Clarification to Commercial Prior Authorization Requirements for Early Intensive Behavioral Intervention (EIBI)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 10, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P53-17 New Drug-Related Prior Authorization Requirements for Edaravone (Radicava) and Cerliponase Alfa (Brineura)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 10, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP31-17 New Pre-Authorization Form for Infliximab
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 05, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P52-17 New Drug-Related Prior Authorization with Quantity Limit Criteria: Parathyroid Hormone Analog for Osteoporosis
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအီးကထိဘၢၣ် 03, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP30-17 Disclosure of Ownership Form
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 25, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P49-17 Two New Medicare Advantage Prescription Drug Products in 2018
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 25, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P50-17 Provider Data Accuracy and Identified Lack of Claim Submissions
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 25, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP29-17 Pharmacy Benefit Exclusion for Kymriah
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 21, 2017